1FW2:F:F-WUXI BIOLOGICS-00000083 (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.3218

Change

0.00 (0.00)%

Market Cap

USD 6.01B

Volume

890.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

-0.20 (-0.19%)

USD 474.00B
NOVA:F Novo Nordisk A/S

+0.50 (+0.48%)

USD 471.87B
RGO:F Regeneron Pharmaceuticals Inc

-17.00 (-1.81%)

USD 104.28B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 85.13B
CSJ:F CSL Limited

N/A

USD 85.06B
DUL:F Alnylam Pharmaceuticals Inc

-1.30 (-0.53%)

USD 31.84B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.24%)

USD 30.73B
1AEA:F argenx SE

-6.00 (-1.22%)

USD 29.94B
1AE:F Argen-X

+2.60 (+0.53%)

USD 29.76B
22UA:F BioNTech SE

+0.40 (+0.36%)

USD 25.58B

ETFs Containing 1FW2:F

FID First Trust Intl Multi-As.. 1.92 % 0.69 %

+0.16 (+2.79%)

USD 0.08B
SCZ iShares MSCI EAFE Small-C.. 0.08 % 0.39 %

+0.59 (+2.79%)

USD 9.37B
DVYA iShares Asia/Pacific Divi.. 0.00 % 0.49 %

+0.15 (+2.79%)

N/A
EWH iShares MSCI Hong Kong ET.. 0.00 % 0.48 %

+0.55 (+2.79%)

N/A
FGD First Trust Dow Jones Glo.. 0.00 % 0.58 %

+0.02 (+2.79%)

N/A
IFGL iShares International Dev.. 0.00 % 0.48 %

-0.13 (2.79%)

USD 0.11B
INTF iShares Edge MSCI Multifa.. 0.00 % 0.30 %

+0.26 (+2.79%)

USD 1.22B
IVLU iShares Edge MSCI Intl Va.. 0.00 % 0.30 %

+0.27 (+2.79%)

USD 1.85B
3110:HK Global X Hang Seng High D.. 0.00 % 0.00 %

+0.70 (+2.79%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.61% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.61% 11% F 4% F
Trailing 12 Months  
Capital Gain -70.34% 15% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.34% 15% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.29% 18% F 7% C-
Dividend Return -22.29% 18% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.49% 50% F 36% F
Risk Adjusted Return -68.59% 11% F 5% F
Market Capitalization 6.01B 94% A 81% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.